Smith & Nephew PLC traded at 1,237.75 this Tuesday February 3rd, decreasing 12.75 or 1.02 percent since the previous trading session. Looking back, over the last four weeks, Smith & Nephew lost 0.79 percent. Over the last 12 months, its price rose by 19.76 percent. Looking ahead, we forecast Smith & Nephew PLC to be priced at 1,217.28 by the end of this quarter and at 1,146.05 in one year, according to Trading Economics global macro models projections and analysts expectations.
Smith & Nephew plc is a portfolio medical technology company. The Company is engaged in developing, manufacturing, marketing, and selling medical devices and services. It is focused on the repair, regeneration, and replacement of soft and hard tissue. Its segments include Orthopaedics, Sports Medicine & ENT and Advanced Wound Management. Its Orthopaedics segment includes a range of hip and knee Implants used to replace diseased, damaged or worn joints, robotics-assisted and digital enabling technologies and services that help surgeons, and trauma products used to stabilize severe fractures and correct hard tissue deformities. Its Sports Medicine & Ear, Nose and Throat (ENT) businesses offer advanced products and instruments used to repair or remove soft tissue. Its Advanced Wound Management portfolio provides a comprehensive set of products to meet broad and complex clinical needs, and to help healthcare professionals reduce the human and economic consequences of wounds.